Go to the list of all blogs
Allana's Avatar
published in Blogs
Sep 25, 2026
SRTY vs TZA: Comparing Two -3x Inverse Russell 2000 ETFs

SRTY vs TZA: Comparing Two -3x Inverse Russell 2000 ETFs

Key Takeaways

  • Both SRTY and TZA aim for daily results equal to three times the inverse (-3x) of the Russell 2000 Index, positioning them as structurally similar leveraged inverse ETFs suited mainly for short-term tactical applications.
  • SRTY features a net expense ratio of 0.95%, a modest edge over TZA’s 0.99%, which could matter for longer tactical holds.
  • Each fund relies on synthetic exposure via swaps, futures, and cash equivalents instead of direct stock ownership, leading to limited traditional diversification and notable sensitivity to daily compounding.
  • The underlying Russell 2000 Index focuses on U.S. small-cap companies, with key sector weights in health care (around 20%), financials (around 18%), and industrials (around 15%).
  • Liquidity levels are adequate for both products, supporting use by institutional and retail investors looking for short-term inverse small-cap exposure.
  • These ETFs provide amplified downside participation distinct from long-only small-cap vehicles, yet they require active monitoring and are not designed for multi-day holds without oversight due to volatility decay.

Why These ETFs Stand Out

ProShares UltraPro Short Russell2000 (SRTY) and Direxion Daily Small Cap Bear 3X ETF (TZA) offer closely matched choices for investors seeking leveraged inverse exposure to U.S. small-cap equities. Instead of competing with traditional long-only small-cap funds, these products support hedging strategies or bearish outlooks on the Russell 2000 Index. Their similar structures make them worth comparing when small-cap volatility or sector shifts affect positioning and risk decisions.

An Overview of SRTY

SRTY targets daily results, before fees and expenses, that correspond to three times the inverse (-3x) of the Russell 2000 Index’s daily performance. It uses a synthetic approach built on swaps, futures contracts, and cash equivalents, resulting in a portfolio of roughly 10–15 holdings centered on these instruments. Sector exposures track the benchmark, with emphasis on health care, financials, and industrials. The net expense ratio is 0.95%. As a passive vehicle with daily rebalancing, SRTY resets its exposure each trading day, setting it apart from unleveraged or long-only small-cap options. I also checked this using Tickeron’s AI Screener to see how the ETF compares to others in the category.

An Overview of TZA

TZA follows the same primary goal: daily investment results, before fees and expenses, equal to three times the inverse (-3x) of the Russell 2000 Index. It similarly depends on swaps, futures, and cash instruments, producing a compact portfolio of about 12 holdings. Sector allocations track the small-cap benchmark closely, led by health care, financials, and industrials. The net expense ratio stands at 0.99%. Daily rebalancing keeps the leveraged inverse target intact, framing the fund as a tactical instrument in the inverse equity space.

The Russell 2000 Context

The Russell 2000 Index includes roughly 2,000 U.S. small-capitalization companies across varied sectors, with meaningful allocations to health care, financials, and industrials. Factors such as interest rate expectations, economic growth paths, and credit conditions often shape small-cap cycles. Regulatory changes in lending, healthcare, or energy can act as triggers, while earnings variability and liquidity issues represent ongoing risks in this segment. Flows into or out of small-cap equities tend to reflect broader risk appetite and rotation trends over market cycles.

Performance and Positioning Insights

Across recent market cycles, both SRTY and TZA have shown the amplified volatility expected from their -3x daily objectives, with returns drifting from the index over multi-day periods because of compounding effects. Relative positioning reveals small cost differences, where SRTY’s lower expense ratio may offer a slight efficiency benefit during sustained inverse exposure. Volatility levels stay comparable given matching leverage and benchmark focus, although liquidity nuances can affect execution during busy trading sessions. Sector trends within the Russell 2000, particularly in healthcare and financials, continue to shape performance for both products over longer horizons.

How I Use Tickeron’s AI Screener

In my research process, I often turn to Tickeron’s AI Screener to filter ETFs and stocks by technical patterns, fundamentals, trends, and volatility signals. It allows quick scans across thousands of securities with customizable criteria like industry, market cap, and performance metrics, helping surface relevant ideas more efficiently than manual review. This tool has proven useful when evaluating inverse products like these for short-term positioning.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SRTY, TZA

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Momentum Indicator for SRTY turns positive, indicating new upward trend

SRTY saw its Momentum Indicator move above the 0 level on August 20, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In 84 of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for SRTY just turned positive on August 20, 2026. Looking at past instances where SRTY's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.

SRTY moved above its 50-day moving average on August 28, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for SRTY crossed bullishly above the 50-day moving average on September 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +4.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRTY advanced for three days, in 244 of 268 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

The Aroon Indicator entered an Uptrend today. In 159 of 175 cases where SRTY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The 10-day RSI Indicator for SRTY moved out of overbought territory on September 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 24 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 52 of 55 cases where SRTY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRTY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

SRTY broke above its upper Bollinger Band on September 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Industry description

The investment seeks daily investment results that correspond to three times the inverse (-3x) of the daily performance of the Russell 2000® Index. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a measure of small-cap U.S. stock market performance. Under normal circumstances, the fund will obtain inverse leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.
View a ticker or compare two or three
SRTY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Trading

Category
Trading--Inverse Equity
Address
ProShares Trust7501 Wisconsin Avenue,Suite 1000Bethesda
Phone
N/A
Web
www.proshares.com
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.